hellebrigenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hellebrigenin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	259577
CHEMBL ID	2068960
SCHEMBL ID	13188019
MeSH ID	M0041462

Synonyms (23)

Synonym
nsc-89594
bufotalidin
465-90-7
nsc89594
hellebrigenin
einecs 207-368-3
5-beta-bufa-20,22-dienolide, 3-beta,5,14-trihydroxy-19-oxo-
nsc 89594
bufa-20,22-dienolide, 3,5,14-trihydroxy-19-oxo-, (3beta,5beta)-
brn 0056259
19-oxo-3-beta,5,14-trihydroxy-5-beta-bufa-20,22-dienolide
C16969
(3s,5s,8r,9s,10s,13r,14s,17r)-3,5,14-trihydroxy-13-methyl-17-(6-oxopyran-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde
5-18-05-00180 (beilstein handbook reference)
CHEMBL2068960
SCHEMBL13188019
CS-0034272
HY-N6576
3,5,14-trihydroxy-19-oxobufa-20,22-dienolide
DTXSID90963594
bufa-20,22-dienolide,3,5,14-trihydroxy-19-oxo-,(3beta,5beta)-
MS-27249
AKOS040760445

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" Measurements of the inotropic effects in guinea pig left atria performed at concentrations of acrihellin kept constant yielded a dose-response curve, which closely resembles that of the conventional cardioactive steroid ouabain."	( Acrihellin, a cardioactive steroid escaping from the organ-bath. Herzig, S; Lüllmann, H; Mohr, K; Seemann, B, 1987)	0.27

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID155909	Inhibitory activity against colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/5	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1764996	Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
AID1765003	Inhibition of VEGFR2 mediated angiogenesis in transgenic Tg(flk1:GFP) zebra fish embryo at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
AID155910	Inhibitory activity against the primary liver carcinoma (PLC) cell line PLC/PRF/5	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1765007	Toxicity in zebra fish larvae assessed as pericardial edema at 100 uM measured at 48 hpf by stereomicroscopic analysis
AID1764999	Induction of apoptosis in human SK-MEL cells assessed as increase in cleaved PARP level at 0.2 to 0.8 uM incubated for 48 hrs by Western blot analysis
AID1765001	Antiangiogenic activity in transgenic Tg(fli1:GFP) zebra fish embryo assessed as reduction in intersegmental blood vessels at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
AID1765002	Antiangiogenic activity in transgenic Tg(fli1:GFP) zebra fish embryo assessed as reduction in angiogenic sprouts at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (22.22)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (11.11)	29.6817
2010's	4 (44.44)	24.3611
2020's	2 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	24.46 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	5.12 (4.65)
Search Engine Demand Index	23.28 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (24.46)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.08	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
periplogenin periplogenin: structure	2.01	1
sb 203580 [no description available]	2.17	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
cinobufotalin cinobufotalin: RN given refers to (3beta,5beta,15beta,16beta)-isomer; RN for cpd without isomeric designation not avail 4/90	2.01	1
Gamabufogenin gamabufotalin: antiangiogenic, main active compound isolated from Chinese medicine Chansu; structure in first source	2.01	1	steroid lactone
telocinobufagin telocinobufagin: structure	2.01	1	steroid lactone
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	1.97	1	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
glycosides [no description available]	2.25	1
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	1.96	1	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
digitoxigenin Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin.. digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22).	2.01	1	14beta-hydroxy steroid; 3beta-hydroxy steroid
acrihellin acrihellin: structure given in first source	1.97	1
bufogenin bufogenin: respiratory stimulant; from toad; structure. bufogenin : A steroid lactone of Chan su (toad venom), a Chinese medicine obtained from the skin venom gland of toads. A specific Na/K-ATPase protein inhibitor, it is used as a cardiotonic and central nervous system (CNS) respiratory agent, an analgesic and anesthetic, and as a remedy for ulcers.	2.01	1	epoxy steroid; steroid lactone	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
bufalin bufalin: cardiotonic; powerful anesthetic & one of the active constituents of the Chinese drug ch'an su(senso); in Japan prepared from skin of Bufo bufo garfarizans; RN given refers to (3beta,5beta)-isomer. bufalin : A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo.	2.01	1	14beta-hydroxy steroid; 3beta-hydroxy steroid	animal metabolite; anti-inflammatory agent; antineoplastic agent; cardiotonic drug
hellebrin hellebrin: from Helleborus purpurascens (Ranunculaceae)	7.71	3	alpha-L-rhamnoside; disaccharide derivative
desacetylcinobufagin desacetylcinobufagin: structure in first source	2.01	1
cinobufagin cinobufagin: isolated from Chinese medicinal preparation ch'an su; derived from toad venom	2.01	1	steroid lactone
bufotalin bufotalin: from toads; structure	2.44	2	steroid lactone
arenobufagin arenobufagin: structure given in first source	7.17	1	steroid lactone

Condition	Relationship Strength	Studies
Cancer of Liver [description not available]	2.44	2
Liver Neoplasms Tumors or cancer of the LIVER.	2.44	2
Benign Neoplasms, Brain [description not available]	2.17	1
Astrocytoma, Grade IV [description not available]	2.17	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.17	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	7.17	1
Benign Neoplasms [description not available]	2.08	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.08	1
Hepatocellular Carcinoma [description not available]	7.1	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.1	1

chemdatabank.com